340450 — GC Genome Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩170bn
- KR₩127bn
- KR₩26bn
Annual cashflow statement for GC Genome, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | — | -550 | -1,257 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | — | 1,447 | 834 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -1,610 | -1,097 | -2,418 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -1,610 | 3,340 | 378 |
| Capital Expenditures | -4,070 | -7,455 | -416 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | 9,247 | -5,021 | 3,544 |
| Sale of Fixed Assets | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | 5,177 | -12,476 | 3,128 |
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | -672 | -859 | -616 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 2,894 | -10,000 | 2,891 |